Valuation: Codexis, Inc.

Market Cap 182M 156M 146M 133M 251M 17.41B 254M 1.72B 671M 8.74B 683M 668M 28.92B P/E 2026 *
-4.47x
P/E 2027 * -5.8x
Enterprise Value 182M 156M 146M 133M 251M 17.41B 254M 1.72B 671M 8.74B 683M 668M 28.92B EV / Sales 2026 *
2.45x
EV / Sales 2027 * 2.06x
Free-Float
93.85%
Yield 2026 *
-
Yield 2027 * -
1 day-0.60%
1 week+4.40%
Current month+18.57%
1 month+12.16%
3 months-33.33%
6 months+50.23%
Current year+1.84%
1 week 1.51
Extreme 1.51
1.76
1 month 1.38
Extreme 1.38
1.76
Current year 0.96
Extreme 0.9583
2.98
1 year 0.96
Extreme 0.9583
2.98
3 years 0.96
Extreme 0.9583
6.08
5 years 0.96
Extreme 0.9583
42.01
10 years 0.96
Extreme 0.9583
42.01
Manager TitleAgeSince
Chief Executive Officer 59 2025-11-06
Director of Finance/CFO 59 2024-09-29
Chief Tech/Sci/R&D Officer 56 2020-05-04
Director TitleAgeSince
Director/Board Member 66 2016-02-29
Director/Board Member 59 2025-11-06
Chairman 66 -
Date Insider Type Main position Quantity % Market Cap.
2/23/26 Free

Chief Financial Officer

316,100 0.3500%
2/23/26 Sell

Chief Technology Officer

321,962 0.3565%
2/23/26 Free

Chief Executive Officer

993,000 1.0994%
Change 5-day change 1-year change 3-year change Capi.($)
-0.60%+4.40%-42.46%+1.84% 182M
-0.74%+3.78%+3.74%+23.10% 51.21B
+1.01%-0.20%+471.68%+564.93% 45.35B
+0.16%+7.88%+36.14%+20.76% 42.84B
-0.66%+2.61%+18.59%+87.04% 42.29B
+0.88%-3.48%+17.20%+53.83% 32.15B
-0.12%+3.84%+33.73%+145.25% 17.31B
-0.53%+1.84% - - 16.55B
+0.58%+4.66%+7.17%+30.87% 14.84B
+1.15%+4.17%+84.49%+50.33% 14.25B
Average +0.11%+3.34%+70.03%+108.66% 27.7B
Weighted average by Cap. +0.11%+3.07%+101.21%+141.28%

Financials

2026 *2027 *
Net sales 74.09M 63.49M 59.4M 54.3M 102M 7.09B 104M 703M 273M 3.56B 278M 272M 11.79B 88.44M 75.79M 70.9M 64.82M 122M 8.47B 124M 839M 326M 4.25B 332M 325M 14.07B
Net income -36.35M -31.15M -29.14M -26.64M -50.28M -3.48B -50.82M -345M -134M -1.75B -136M -134M -5.78B -28.54M -24.46M -22.88M -20.92M -39.48M -2.73B -39.9M -271M -105M -1.37B -107M -105M -4.54B
Net Debt - -
Logo Codexis, Inc.
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Employees
146
Date Price Change Volume
26-08-24 US$1.660 -0.60% 1,359,790
26-08-21 US$1.670 +5.70% 1,257,998
26-08-20 US$1.580 -1.25% 1,282,390
26-08-19 US$1.600 +6.67% 1,984,388
26-08-18 US$1.500 -5.66% 940,063
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.660USD
Average target price
6.333USD
Spread / Average Target
+281.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CDXS Stock